Telesis Bio is a synthetic biology tools company that makes instruments, software, and reagent kits to help researchers synthesize DNA and mRNA. The core product is the BioXp system, a benchtop automated workstation that takes a researcher from a digital sequence to a finished synthetic DNA or mRNA product in under 24 hours — replacing a process that traditionally required days or weeks of manual lab work or outsourcing to a CRO. Telesis Bio follows a razor-and-blades model: the BioXp instrument drives recurring sales of application-specific reagent kits consumed each time a researcher runs a synthesis workflow. Revenue scales with the number of installed BioXp systems and how intensively customers use them. As of end of FY23, Telesis Bio had placed roughly 300 BioXp systems globally across approximately 500 customers, including 17 of the 20 largest biopharma companies. A newer platform, Gibson SOLA, is designed to run on third-party lab hardware, potentially expanding Telesis Bio's addressable market beyond BioXp users. Telesis Bio also earns lumpy milestone-based licensing revenue from a collaboration with Pfizer focused on enzymatic DNA synthesis for mRNA vaccines. A separate services business, Eton, provides DNA sequencing and oligo synthesis to academic and biopharma customers, though this is more commoditized and operates somewhat independently from the core BioXp platform.